Literatur

• Literatur

• 1 Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292 (07) 344-7.
• 2 Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292 (08) 403-7.
• 3 Hengstman GJ, van Engelen BG, van Venrooij WJ. Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations. Curr Opin Rheumatol 2004; 16 (06) 692-9.
• 4 Mammen AL. Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010; 1184: 134-53.
• 5 Dalakas MC. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol 2010; 10 (03) 346-52.
• 6 Dalakas M, Karpati G. In: Karpati G. et al. Disorders of voluntary muscle. 8th ed.. Cambridge: University Press; 2010
• 7 Euwer RL, Sontheimer RD. Amyopathic dermatomyositis (dermatomyositis sine myositis). Presentation of six new cases and review of the literature. J Am Acad Dermatol 1991; 24 (6 Pt 1): 959-66.
• 8 Lam WW. et al. MR imaging in amyopathic dermatomyositis. Acta Radiol 1999; 40 (01) 69-72.
• 9 Gerami P. et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006; 54 (04) 597-613.
• 10 Azuma K. et al. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis. Mod Rheumatol 2010; 21 (02) 178-83.
• 11 Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984; 16 (02) 193-208.
• 12 van der Meulen MF. et al. Polymyositis: an overdiagnosed entity. Neurology 2003; 61 (03) 316-21.
• 13 Gallardo E, de Andres I, Illa I. Cathepsins are upregulated by IFN-gamma/STAT1 in human muscle culture: a possible active factor in dermatomyositis. J Neuropathol Exp Neurol 2001; 60 (09) 847-55.
• 14 Troyanov Y. et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005; 84 (04) 231-49.
• 15 Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum 1980; 23 (08) 881-8.
• 16 Targoff IN. Autoantibodies and their significance in myositis. Curr Rheumatol Rep 2008; 10 (04) 333-40.
• 17 Stone KB. et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 2007; 56 (09) 3125-31.
• 18 Yoshifuji H. et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 2006; 39 (03) 233-41.
• 19 Hengstman GJ. et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis 2006; 65 (02) 242-5.
• 20 Okada S. et al. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum 2003; 48 (08) 2285-93.
• 21 Burd CJ, Kinyamu HK, Miller FW, Archer TK. UV radiation regulates Mi-2 through protein translation and stability. J Biol Chem 2008; 283 (50) 34976-82.
• 22 Reeves WH, Nigam SK, Blobel G. Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci USA 1986; 83 (24) 9507-11.
• 23 Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73 (04) 420-8.
• 24 Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004; 50 (01) 209-15.
• 25 Targoff IN. et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54 (11) 3682-9.
• 26 Kaji K. et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007; 46 (01) 25-8.
• 27 Gunawardena H. et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008; 47 (03) 324-8.
• 28 Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 2009; 48 (06) 607-12.
• 29 Labirua A, Lundberg IE. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol 2010; 22 (06) 633-8.
• 30 Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senecal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 2007; 09 (04) R78.
• 31 Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol 2007; 19 (06) 523-9.
• 32 Vancsa A. et al. Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: Relevance for clinical classification: retrospective study of 169 patients. Joint Bone Spine 2010; 77 (02) 125-30.
• 33 Hall S, Hanrahan P. Muscle involvement in mixed connective tissue disease. Rheum Dis Clin North Am 2005; 31 (03) 509-17.
• 34 Rutjes SA. et al. Anti-Ro52 antibodies frequently cooccur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997; 109 (01) 32-40.
• 35 Vancsa A. et al. Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol Int 2009; 29 (09) 989-94.
• 36 Emslie-Smith AM, Engel AG. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology 1991; 41 (06) 936-9.
• 37 Authier FJ, Kondo H, Ghnassia RT, Revuz J, Gherardi RK. Necrotizing myopathy with pipestem capillaries and minimal cellular infiltration: a case associated with cutaneous signs of dermatomyositis. Neurology 1996; 46 (05) 1448-51.
• 38 Dimitri D, Andre C, Roucoules J, Hosseini H, Humbel RL, Authier FJ. Myopathy associated with antisignal recognition peptide antibodies: clinical heterogeneity contrasts with stereotyped histopathology. Muscle Nerve 2007; 35 (03) 389-95.
• 39 Sampson JB. et al. Paraneoplastic myopathy: response to intravenous immunoglobulin. Neuromuscul Disord 2007; 17 (05) 404-8.
• 40 Lundberg IE. The heart in dermatomyositis and polymyositis. Rheumatology (Oxford) 2006; 45 Suppl (Suppl. 04) iv 18-21.
• 41 Denbow CE, Lie JT, Tancredi RG, Bunch TW. Cardiac involvement in polymyositis: a clinicopathologic study of 20 autopsied patients. Arthritis Rheum 1979; 22 (10) 1088-92.
• 42 Jordan B, Eger K, Zierz S. [Polymyositis associated with thymoma]. Nervenarzt 2009; 80 (06) 708-11.
• 43 Riemekasten G. et al. Beware of the heart: the multiple picture of cardiac involvement in myositis. Rheumatology (Oxford) 1999; 38 (11) 1153-7.
• 44 Fathi M. et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008; 59 (05) 677-85.
• 45 Sato S. et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52 (05) 1571-6.
• 46 Nakashima R. et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 2010; 49 (03) 433-40.
• 47 Mukae H. et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 2009; 136 (05) 1341-7.
• 48 Chinoy H. et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006; 08 (01) R13.
• 49 Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol 2010; 06 (03) 129-37.
• 50 Kim J, Kim YW, Lee SM, Kim YS, Kim YT, Song YW. Successful lung transplantation in a patient with dermatomyositis and acute form of interstitial pneumonitis. Clin Exp Rheumatol 2009; 27 (01) 168-9.
• 51 Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001; 134 (12) 1087-95.
• 52 Madan V, Chinoy H, Griffiths CE, Cooper RG. Defining cancer risk in dermatomyositis. Part I. Clin Exp Dermatol 2009; 34 (04) 451-5.
• 53 Cao H, Parikh TN, Zheng J. Amyopathic dermatomyositis or dermatomyositis-like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis. Clin Rheumatol 2009; 28 (08) 979-84.
• 54 Hill CL. et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a populationbased study. Lancet 2001; 357 (9250): 96-100.
• 55 Trallero-Araguas E. et al. Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore) 2010; 89 (01) 47-52.
• 56 Madan V, Chinoy H, Griffiths CE, Cooper RG. Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology. Clin Exp Dermatol 2009; 34 (05) 561-5.
• 57 Selva-O’Callaghan A. et al. Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis. Am J Med 2010; 123 (06) 558-62.
• 58 Ponyi A. et al. Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci 2005; 1051: 64-71.
• 59 Schoser BG. Ocular myositis: diagnostic assessment, differential diagnoses, and therapy of a rare muscle disease – five new cases and review. Clin Ophthalmol 2007; 01 (01) 37-42.
• 60 Bau V, Sievert M, Roggenkamper P, Zierz S. Cyclic vertical deviation after ocular myositis and treatment by recession of the inferior rectus muscle. Graefes Arch Clin Exp Ophthalmol 2005; 243 (10) 1062-5.
• 61 Krasnianski M, Sievert M, Bau V, Zierz S. External ophthalmoplegia due to ocular myositis in a patient with ophthalmic herpes zoster. Neuromuscul Disord 2004; 14 (07) 438-41.
• 62 Jacobs D, Galetta S. Diagnosis and management of orbital pseudotumor. Curr Opin Ophthalmol 2002; 13 (06) 347-51.
• 63 Dalakas MC. Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future. Neuromuscul Disord 2006; 16 (04) 223-36.